Life-saving discoveries
At VCU Massey Comprehensive Cancer Center, you’ll have access to the most advanced therapies and the latest technologies. Some of these therapies were discovered and developed right here at Massey, where our doctors collaborate closely with our research scientists to bring new research breakthroughs to patients in the form of clinical trials. Clinical trials are research studies that help the medical community discover new and better ways to prevent, diagnose, treat and cure diseases. With one of the largest selections of cancer clinical trials in Virginia, Massey gives patients expanded treatment options and new hope every day.
Below are some of the exciting clinical trials options available at Massey for patients with gynecologic cancers. To learn more about any of these trials, please contact Sonya Washington, R.N., clinical research nurse coordinator, at (804) 628-2582 or email [email protected].
GOG-3030: A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
This is a Phase 3 clinical trial testing an immunotherapy drug called atezolizumab for the treatment of metastatic or recurrent cervical cancer. Atezolizumab is an immunotherapy drug that targets the PD-L1 protein to help the immune system recognize and attack cancer cells. It has been approved to treat aggressive lung, breast and liver cancers, but this is the first time it’s being tested for cervical cancer.
Participants in the clinical trial will be randomized into two groups, one receiving the experimental therapy and the other receiving the current standard of care. Both groups will be closely monitored during and after treatment for side effects and treatment responses.
AK104-201-AU: A Phase 2, multicenter, single-arm, open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer.
This is a Phase 2 clinical trial testing a new, experimental immunotherapy drug known as AK104 for patients with recurrent or metastatic cervical cancer. AK104 is a promising immunotherapy drug that has already shown responses in a small number of women. It targets two proteins, PD-1 and CTLA-4, to enhance the immune system’s ability to destroy cancer
NRG-GY009: A Phase 2 / 3 Study Comparing Three Drug Regimens Using Liposomal Doxorubicin, Bevacizumab, and/or Atezolizumab Immunotherapy to Treat Recurrent or Persistent Ovarian Cancer
This study evaluates the addition of the immunotherapy drug atezolizumab to the current standard therapy of liposomal doxorubicin and bevacizumab to treat ovarian cancer resistant to platinum-based chemotherapy. Atezolizumab targets a protein that helps the immune system recognize and attack cancer cells. It is already approved for the treatment of bladder and lung cancer.
GOG-3048: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 in Patients with Solid Tumors Likely to Express NaPi2b (Ovarian & NSCLC)
This Phase 1b clinical trial will establish the recommended tolerated dose of XMT-1536 for women with platinum-resistant, high-grade serous ovarian cancer and non-small cell lung cancer. XMT-1536 is an experimental drug targeting NaPi2b, a tumor-associated antigen (TAA) that is expressed on a variety of cancer cells.
Participants will receive XMT-1536 as an infusion once every four weeks. After the first cycle, participants may continue to receive XMT-1536 until disease progression provided the drug is well-tolerated and they continue to derive clinical benefit.
NRG-GY021: A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
This Phase 2 clinical trial will test if the addition of tremelimumab improves the standard treatment for platinum-sensitive recurrent ovarian cancer. The current standard treatment is olaparib, a medication known as a PARP inhibitor. Tremelimumab is an investigational immunotherapy drug that blocks the CTLA4 protein to potentially enhance the immune system’s ability to fight cancer. This study will determine if adding tremelimumab helps prevent cancer growth and spread.
This study is for women with ovarian, fallopian tube or peritoneal cancer that has not come back within six months of receiving platinum-based treatments. Patients will be randomly assigned to receive olaparib alone or olaparib plus tremelimumab.
NRG-GY020: A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
This Phase 3 trial compares whether the addition of pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer coming back (recurrence) in patients with newly diagnosed stage I-II endometrial cancer.
Pembrolizumab is an immunotherapy that helps the body recognize and attack cancer cells. The addition of pembrolizumab to radiation treatment may be more effective than radiation treatment alone in reducing cancer recurrence.
NRG-GY005: A Randomized Phase 2/3 Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
This randomized Phase 2 / 3 trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum or continued to grow while being treated with platinum-based chemotherapy drugs.
Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.
NRG-CC008: This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations. Women with BRCA1 mutations may opt to undergo the surgical removal of both their fallopian tubes and ovaries (bilateral salpingo-oophorectomy) in order to reduce their risk of cancer. However, many women may wish to only remove their fallopian tubes (bilateral salpingectomy) initially and remove their ovaries at a later date. This study may help doctors determine the comparative cancer risk reduction of both surgical approaches.
Learn more about clinical trials at Massey
